Clinical Trial Update: 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study using the PSMA PET imaging agent 18F-DCFPyL to assess treatment response to stereotactic body radiotherapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-DCFPyL (DCFPyL radiotracer for PSMA imaging)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Localized Prostate Cancer | Phase 2 | Status: RECRUITING